Anne Lynn S Chang Selected Research

Basal Cell Carcinoma (Rodent Ulcer)

1/2022	Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.
1/2021	Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
2/2019	Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study.
1/2019	Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion.
1/2019	Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment.
4/2018	A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery.
1/2018	An exploratory open-label, investigator-initiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas.
1/2017	Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities.
1/2017	Commentary on Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment.
11/2016	Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anne Lynn S Chang Research Topics

Disease

34	Basal Cell Carcinoma (Rodent Ulcer) 01/2022 - 06/2012
20	Neoplasms (Cancer) 08/2019 - 06/2012
12	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 09/2014
4	Basal Cell Nevus Syndrome (Gorlin Syndrome) 01/2016 - 05/2013
3	Skin Neoplasms (Skin Cancer) 06/2014 - 12/2010
3	Hyperpigmentation 01/2011 - 12/2006
3	Erythema 01/2011 - 07/2009
2	Nevus (Nevi) 01/2022 - 01/2016
2	Pain (Aches) 01/2021 - 04/2008
2	Wounds and Injuries (Trauma) 10/2019 - 09/2010
2	Neoplasm Metastasis (Metastasis) 01/2017 - 08/2014
2	Melanoma (Melanoma, Malignant) 01/2016 - 11/2012
2	Rosacea (Acne Rosacea) 06/2015 - 03/2012
2	Acne Vulgaris 03/2012 - 03/2009
2	Telangiectasis (Telangiectasia) 12/2010 - 07/2009
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2022
1	Weight Loss (Weight Reduction) 01/2022
1	Ageusia (Hypogeusia) 01/2022
1	Spasm (Spasms) 01/2022
1	Dysgeusia (Parageusia) 01/2022
1	Alopecia (Baldness) 01/2022
1	Inflammation (Inflammations) 01/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021
1	Herpes Labialis (Fever Blister) 12/2020
1	Multiple Myeloma 09/2020
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2019
1	Dermatitis 12/2018
1	Chickenpox 07/2018
1	Basal Cell Neoplasms (Basal Cell Cancer) 01/2018
1	Atopic Dermatitis (Atopic Eczema) 01/2018
1	Synucleinopathies 01/2018
1	Anosmia 01/2018
1	Pruritus (Itching) 01/2018
1	Body Weight (Weight, Body) 01/2018
1	Squamous Cell Carcinoma of Head and Neck 01/2017
1	Lentigo (Lentiginosis) 01/2016
1	Lung Diseases (Lung Disease) 08/2014
1	Disease Progression 01/2014
1	Carcinoma (Carcinomatosis) 05/2013
1	Keratoacanthoma 02/2013
1	Medulloblastoma 10/2012
1	Skin Ulcer 04/2009
1	Lichen Planus (Lichen Ruber Planus) 04/2008
1	Argyria 12/2006

Drug/Important Bio-Agent (IBA)

18	HhAntag691IBA 01/2022 - 06/2012
6	cemiplimabIBA 01/2021 - 01/2018
5	Immune Checkpoint InhibitorsIBA 08/2019 - 01/2016
4	sonidegibIBA 01/2018 - 06/2015
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 06/2015
3	Pharmaceutical PreparationsIBA 08/2015 - 01/2011
2	RNA (Ribonucleic Acid)IBA 10/2019 - 01/2019
2	pembrolizumabIBA 02/2019 - 01/2016
1	squaric acid dibutyl esterIBA 12/2020
1	Immunoglobulins (Immunoglobulin)IBA 01/2020
1	Monoclonal AntibodiesIBA 01/2020
1	CytokinesIBA 10/2019
1	LigandsIBA 08/2019
1	Programmed Cell Death 1 ReceptorIBA 01/2019
1	ChromatinIBA 01/2019
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2019
1	NVP-BKM120IBA 01/2018
1	alpha-SynucleinIBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	Filaggrin ProteinsIBA 01/2018
1	CeramidesIBA 01/2018
1	Colloids (Colloid)IBA 01/2018
1	P-2 (P 2)IBA 01/2017
1	B7-H1 AntigenIBA 01/2017
1	Arsenic Trioxide (Trisenox)FDA Link 04/2016
1	Messenger RNA (mRNA)IBA 04/2016
1	Itraconazole (Sporanox)FDA LinkGeneric 04/2016
1	IpilimumabIBA 01/2016
1	Nitrogen DioxideIBA 01/2016
1	Cisplatin (Platino)FDA LinkGeneric 01/2016
1	HLA-DRB1*03:01 antigenIBA 06/2015
1	HLA-DQB1 antigen (HLA DQB1)IBA 06/2015
1	HLA-DR alpha-ChainsIBA 06/2015
1	HLA-DQA1 antigen (HLA DQA1)IBA 06/2015
1	Clindamycin (Cleocin)FDA LinkGeneric 03/2012
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 03/2012
1	clindamycin phosphate (Clindets)FDA LinkGeneric 03/2012
1	hydroquinone (Esoterica)FDA Link 01/2011
1	hydroxide ionIBA 12/2010
1	Vitamin D FDA LinkGeneric 12/2010
1	Guanosine Triphosphate (GTP)IBA 07/2009
1	Oral ContraceptivesIBA 03/2009
1	Prostaglandins AIBA 04/2008
1	Alefacept (Amevive)FDA Link 04/2008

Therapy/Procedure

18	Therapeutics 01/2021 - 09/2010
4	Radiotherapy 04/2018 - 01/2014
3	Skin Care 01/2018 - 04/2009
2	Mohs Surgery (Mohs' Micrographic Surgery) 01/2022 - 12/2013
1	Rejuvenation 10/2019
1	Percutaneous Collagen Induction 07/2018
1	Adjuvant Chemoradiotherapy 01/2017
1	Precision Medicine 06/2014
1	Drug Therapy (Chemotherapy) 01/2014
1	Neoadjuvant Therapy 05/2013
1	Massage (Zone Therapy) 11/2012
1	Negative-Pressure Wound Therapy 09/2010